about
First-in-human phase I study of pictilisib (GDC-0941), a potent pan-class I phosphatidylinositol-3-kinase (PI3K) inhibitor, in patients with advanced solid tumors.Antitumor activity in RAS-driven tumors by blocking AKT and MEK.Chromatin immunoprecipitation from fixed clinical tissues reveals tumor-specific enhancer profiles.HER kinase inhibition in patients with HER2- and HER3-mutant cancers.The Medical Oncology resident mentor: situation and workloadThird-Line Nivolumab Monotherapy in Recurrent Small Cell Lung Cancer: CheckMate 032Nivolumab Monotherapy and Nivolumab Plus Ipilimumab in Recurrent Small Cell Lung Cancer: Results From the CheckMate 032 Randomized CohortSafety, Tolerability, and Potential Clinical Activity of a Glucocorticoid-Induced TNF Receptor-Related Protein Agonist Alone or in Combination With Nivolumab for Patients With Advanced Solid Tumors: A Phase 1/2a Dose-Escalation and Cohort-ExpansionEfficacy and Determinants of Response to HER Kinase Inhibition in HER2-Mutant Metastatic Breast CancerNBTXR3, a first-in-class radioenhancer hafnium oxide nanoparticle, plus radiotherapy versus radiotherapy alone in patients with locally advanced soft-tissue sarcoma (Act.In.Sarc): a multicentre, phase 2-3, randomised, controlled trialModulation of Fexofenadine Pharmacokinetics by Osimertinib in Patients With Advanced EGFR-Mutated Non-Small Cell Lung CancerTrastuzumab duocarmazine in locally advanced and metastatic solid tumours and HER2-expressing breast cancer: a phase 1 dose-escalation and dose-expansion studyIncreased vulnerability of clinical research units during the COVID-19 crisis and their protection
P50
Q27853088-DF8B7DB7-C8F5-4E24-B005-1130AA80FB51Q35103514-ABBAA63F-F1EA-4843-B126-04C0CC3DBAD8Q38380810-66589FF2-CE32-4827-9D2D-70E7EF939A7FQ50115014-0526D90D-EE47-4DBA-97A1-20C8CF6EA0CBQ57174106-03242731-8C70-44FA-969F-A9ED1298FA49Q57478658-72E87C20-12EF-4AA8-B412-43B8EF9F1F86Q90822787-DADBD2C3-9257-405A-9D71-8EB41DE4B914Q91162715-35B0AEE1-335C-4714-A3FE-9E4CF8E71FD1Q91733989-8CB31CFC-566D-40DF-BCC2-022547CCBAF0Q91806726-6E2DDEE5-490A-4085-B208-D821671077E5Q92387102-1D7E0A8C-E0ED-44B7-B227-BF006AC049A8Q93138554-4ED3153D-6432-4838-9D27-37361D05385AQ96584146-FB067087-B25D-4B9E-A3F8-90D30D502CB2
P50
description
researcher (ORCID 0000-0001-6099-4236)
@en
wetenschapper
@nl
name
V Moreno
@en
V Moreno
@nl
type
label
V Moreno
@en
V Moreno
@nl
prefLabel
V Moreno
@en
V Moreno
@nl
P31
P496
0000-0001-6099-4236